Although APOE/LRP1-regulated pathways have a well-established role in brain Aβ clearance46 the possibility that LRP1 expression can be downregulated by amylin from the luminal side of the blood vessel may represent a novel therapeutic target to reduce AD pathology. The gene discussed is IAPP; the disease is Alzheimer disease.